447 related articles for article (PubMed ID: 31451503)
1. 20S Proteasome as a Drug Target in Trichomonas vaginalis.
O'Donoghue AJ; Bibo-Verdugo B; Miyamoto Y; Wang SC; Yang JZ; Zuill DE; Matsuka S; Jiang Z; Almaliti J; Caffrey CR; Gerwick WH; Eckmann L
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31451503
[TBL] [Abstract][Full Text] [Related]
2. Anti-Trichomonas vaginalis activity of ursolic acid derivative: a promising alternative.
Bitencourt FG; de Brum Vieira P; Meirelles LC; Rigo GV; da Silva EF; Gnoatto SCB; Tasca T
Parasitol Res; 2018 May; 117(5):1573-1580. PubMed ID: 29572567
[TBL] [Abstract][Full Text] [Related]
3. Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis.
Cudmore SL; Delgaty KL; Hayward-McClelland SF; Petrin DP; Garber GE
Clin Microbiol Rev; 2004 Oct; 17(4):783-93, table of contents. PubMed ID: 15489348
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapeutic options for the treatment of human trichomoniasis.
Küng E; Fürnkranz U; Walochnik J
Int J Antimicrob Agents; 2019 Feb; 53(2):116-127. PubMed ID: 30612993
[TBL] [Abstract][Full Text] [Related]
5. Auranofin inactivates Trichomonas vaginalis thioredoxin reductase and is effective against trichomonads in vitro and in vivo.
Hopper M; Yun JF; Zhou B; Le C; Kehoe K; Le R; Hill R; Jongeward G; Debnath A; Zhang L; Miyamoto Y; Eckmann L; Land KM; Wrischnik LA
Int J Antimicrob Agents; 2016 Dec; 48(6):690-694. PubMed ID: 27839893
[TBL] [Abstract][Full Text] [Related]
6. Persistent and recurrent Trichomonas vaginalis infections: epidemiology, treatment and management considerations.
Seña AC; Bachmann LH; Hobbs MM
Expert Rev Anti Infect Ther; 2014 Jun; 12(6):673-85. PubMed ID: 24555561
[TBL] [Abstract][Full Text] [Related]
7. Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis.
Sobel JD; Nyirjesy P; Brown W
Clin Infect Dis; 2001 Oct; 33(8):1341-6. PubMed ID: 11565074
[TBL] [Abstract][Full Text] [Related]
8. In vitro effects of various plants extracts on the growth of Trichomonas vaginalis.
Sharafi SM; Yousefi M; Yousefi HA; Asghari G; Darani HY
Infect Disord Drug Targets; 2013 Oct; 13(5):322-7. PubMed ID: 24712672
[TBL] [Abstract][Full Text] [Related]
9. Trichomoniasis: evaluation to execution.
Harp DF; Chowdhury I
Eur J Obstet Gynecol Reprod Biol; 2011 Jul; 157(1):3-9. PubMed ID: 21440359
[TBL] [Abstract][Full Text] [Related]
10. Trichomoniasis and its treatment.
Nanda N; Michel RG; Kurdgelashvili G; Wendel KA
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):125-35. PubMed ID: 16441214
[TBL] [Abstract][Full Text] [Related]
11. In vitro sensitivity of Trichomonas vaginalis to DNA topoisomerase II inhibitors.
Petmitr PC; Ramdja M; Kajorndechakiat S
Southeast Asian J Trop Med Public Health; 2000 Mar; 31(1):118-22. PubMed ID: 11023077
[TBL] [Abstract][Full Text] [Related]
12. Anti-Trichomonas vaginalis activity of chalcone and amino-analogues.
Trein MR; Rodrigues E Oliveira L; Rigo GV; Garcia MAR; Petro-Silveira B; da Silva Trentin D; Macedo AJ; Regasini LO; Tasca T
Parasitol Res; 2019 Feb; 118(2):607-615. PubMed ID: 30535524
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance in the sexually transmitted protozoan Trichomonas vaginalis.
Dunne RL; Dunn LA; Upcroft P; O'Donoghue PJ; Upcroft JA
Cell Res; 2003 Aug; 13(4):239-49. PubMed ID: 12974614
[TBL] [Abstract][Full Text] [Related]
14. Novel metronidazole-chalcone conjugates with potential to counter drug resistance in Trichomonas vaginalis.
Anthwal A; Rajesh UC; Rawat MS; Kushwaha B; Maikhuri JP; Sharma VL; Gupta G; Rawat DS
Eur J Med Chem; 2014 May; 79():89-94. PubMed ID: 24727243
[TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro cytotoxic effects of ornidazole, metronidazole and ciprofloxacin against Trichomonas vaginalis trophozoites.
Inceboz T; Inceboz U; Ozturk S
J Chemother; 2004 Oct; 16(5):459-62. PubMed ID: 15565912
[TBL] [Abstract][Full Text] [Related]
16. Premature with trichomoniasis: report of one case.
Wang JJ; Yeung LK; Sun LC; Sy LB; Leu FJ
Acta Paediatr Taiwan; 2005; 46(4):219-21. PubMed ID: 16381336
[TBL] [Abstract][Full Text] [Related]
17. Molecular epidemiology of metronidazole resistance in a population of Trichomonas vaginalis clinical isolates.
Snipes LJ; Gamard PM; Narcisi EM; Beard CB; Lehmann T; Secor WE
J Clin Microbiol; 2000 Aug; 38(8):3004-9. PubMed ID: 10921968
[TBL] [Abstract][Full Text] [Related]
18. A case of metronidazole-resistant Trichomonas vaginalis in pregnancy.
Forbes GL; Drayton R; Forbes GD
Int J STD AIDS; 2016 Sep; 27(10):906-8. PubMed ID: 26384945
[TBL] [Abstract][Full Text] [Related]
19. Protocols for the routine screening of drug sensitivity in the human parasite Trichomonas vaginalis.
Natto MJ; Eze AA; de Koning HP
Methods Mol Biol; 2015; 1263():103-10. PubMed ID: 25618339
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of netropsin dihydrochloride against the viability, cytopathogenicity and hemolytic activity of Trichomonas vaginalis clinical isolates.
Abou Gamra MM; Kamel HH; Ezz Eldin HM; Taha Zahran FM
J Infect Chemother; 2019 Dec; 25(12):955-964. PubMed ID: 31189504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
